Yes, MBVX was up 17.12% on a volume of 293,493 but it was down 1.00% AHs. <g>
Volume was 293,493 higher than the 218,872 traded on Dec5, but not as much as the volumes traded in Sep above the 700Ks or the 832,601 traded on Sep19. <g>
On Jan last year, it started the PI of its human antibody for patients with Cancer of the Pancreas.
And the low on Feb16 last year of $0.43 was before the reverse split of 1x7 that took place on Aug17.<g>
And the low on Monday this week of $2.71 would have been $0.36 befrore the RS.<g>
However the stock traded as high as 5914, back in 2003 prior to 1x7 reverse split, when it was still trading as Telik instead of MabVax Therapeutics.<g>
MBVX closed up 6.74% for the week and is still down 4.44% for the month, in spite of having some help from its presentation:
mabvax.com
It seems that its Humab-5B1 antibody potential therapeutic utility extends beyond pancreatic cancer, and may be also effective in neoplasms of lung, colon, urinary bladder, and breast, according to.abstract CT026, Maffuid, AACR 2016 National Meeting.<g>
I sold most of my shares of MBVX, but still hold a few.
My attention to it was brought by the fact that OPKO participated in several of the public offerings, and it seemed that its antibody could be helpful in diagnosing and treating Ca of the pancreas.
Time will tell if that will come out as expected, albeit I don't know if I will live long enough to see the final results. <g>
RAGL,
Bernard
P.S. : Sorry for the long note. I am no longer posting anything on my threads,
and I don't want to have problems with Nigel.<g> |
